Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lapatinib and Paclitaxel in Advanced Platinum Refractory Urothelial Cancer
NCT01700010Phase 2Withdrawn
- Sponsor
- University of Michigan Rogel Cancer Center
- Start
- Nov 2012
- Primary completion
- Jan 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of lapatinib in urothelial carcinoma (UC), sponsored by University of Michigan Rogel Cancer Center. Planned start Nov 2012; status: withdrawn.
02
Drugs
lapatinib
03
Conditions
urothelial carcinoma (UC)
Beyond the preview
Go deeper on NCT01700010.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01700010.